However, previous studies included only small numbers of patients with CIS (n = 22 [11], n = 25 [13]) and provided no longitudinal clinical data on the prognostic relevance of CSF CXCL13 regarding conversion to MS. This evidence concerns the gene CXCL13 and myeloid sarcoma.